A socio economic problem
Addiction is a huge
problem we try to solve.
The market is more than 3 billion USD and involves more than 35M people worldwide
Innovation research and development
With 20 years of experience,
we have developed new strategies to solve addiction problems
An effective treatment
Today, there is no real
solution to addiction.
Our first product,
KT-110,is a true chance of treatment.
European funds
Exceptional participation from Europe to finance clinical trials
Read MoreOur mission : overcome the global challenge of addiction (alcohol, tobacco, cocaine, opioids… )
-
Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…
A phase 2 trial based on the simultaneous blockade of two neurobiological pathways has shown exciting results in patients with severe alcohol use disorder.Read more -
Kinnov Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder
Read moreKinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder.
Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug KT-110. Alcoholism is a major public health issue with a strong unmet medical need.
-
Kinnov-Therapeutics will be present at the 16th International Congress of Addictology
Kinnov-Therapeutics will be present at the 16th International Congress of Addictology of the Albatros in Paris on June 7, 8 and 9, 2022.Read moreTwo conferences will be given: one, presenting the "Cocktail" study, a randomized, placebo-controlled proof-of-concept phase 2 trial, testing the simultaneous blockade of α1b-adrenergic and 5HT2A-serotonergic receptors for the treatment of alcohol use disorder ; the other, presenting the positive results of the "Cocktail" study that strongly suggest that combined prazosin and cyproheptadine can be efficient as a therapy to treat alcoholism in Human.
Here are the abstract of these two conferences : Simultaneous blockade of α1b-adrenergic and 5HT2A-serotonergic receptors for the treatment of alcohol use disorder. Simultaneous blockade of α1b-adrenergic and 5HT2A-serotonergic receptors for the treatment of AUD. Cocktail: Pharmacological rationale. -
Encouraging Results in Kinnov Phase II study !
Read more -
Kinnov-Therapeutics announces the completion of patient recruitment in the alcohol use disorder study (COCKTAIL).
Read more -
Kinnov Therapeutics sera présent au 3ème congrès international Socidrogalcohol
Kinnov Therapeutics sera présent au 3ème congrès international / 48èmes journées nationales de la Socidrogalcohol (société scientifique spécialisée dans les études sur l'alcool et les toxicomanies)Read moreA l'occasion des journées de la Socidrogalcohol qui se tiendront du 21 au 23 octobre 2021 à Barcelone (plus d'informations ici, Kinnov Therapeutics fera une communication orale et présentera un abstract autour de son étude clinique de phase 2 dans la réduction de la consommation d'alcool chez les personnes à troubles d'usage de l'alcool, et pour laquelle la fin du recrutement est prévue pour le 15 juillet 2021.
-
Intervention du Dr Mickael Bisch concernant l’étude clinique KT-110 le 02 décembre 2020 sur France 3 Lorraine
Le docteur Mickael Bisch est intervenu dans l'émission "19/20" de France 3 Lorraine pour le recrutement de patients dans le cadre de l'étude clinique du KT-110 pour lutter contre l'addiction à l'alcool. Voir l'intervention en date du 02 décembre ici (de 8'53 à 12'53) : https://france3-regions.francetvinfo.fr/grand-est/emissions/vos-jt-1213-1920-lorraineRead more -
Trois mois pour réduire sa consommation d’alcool : un appel à volontaires lancé
Le département d’addictologie du Centre psychothérapique de Nancy lance un appel à volontaires pour participer à un essai thérapeutique médicamenteux qui vise les personnes souhaitant reprendre le contrôle de leur consommation d’alcool. https://www.estrepublicain.fr/sante/2020/11/28/nancy-trois-mois-pour-reduire-sa-consommation-d-alcoolRead more -
La société Kinnov-Therapeutics recrute des patients pour son candidat médicament KT-110
La société Kinnov-Therapeutics, filiale de Greenpharma, recrute des patients pour son candidat médicament KT-110 contre l'addiction à l'alcool. L'étude Cocktail est une première en France. 20 CHU, dont celui de Nîmes, vont y participer. Il s'agit de tester les effets de l'association de 2 médicaments pour réduire la consommation excessive d'alcool. Une dizaine de patients du Gard est en cours de sélection pour ensuite évaluer le traitement. https://france3-regions.francetvinfo.fr/occitanie/gard/nimes/nimes-chu-lance-etude-reduction-consommation-alcool-baptisee-cocktail-1896916.htmlRead more -
Kinnov launches Phase 2 study of KT-110 on alcohol addiction
In November 2019, Kinnov launches pivotal phase 2 trial in alcohol addiction, "Cocktail". (more…)Read more
-
Dr Philippe BERNARD
Read moreKinnov Therapeutics CEO
20+ years expertise in Med Chem. Founder and Manager of Greenpharma Is author of more than 50 scientific publications and 20 patents. -
Emmanuel de RIVOIRE
Read moreGeneral Manager
Senior international executive in Pharma industry with 30+ years experience in Europe, Middle East/Africa and Asia. Strong drive, able to manage complex situations. Excellent track record in performances, company transformation and customer culture program. Previous managing experience at Takeda, Nycomed, Roche, GSK, Abbott. -
Dr Fabrice TROVERO
Read more -
Prof Jean-Pol TASSIN
Read moreKT Scientific advisor
Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI.
He is also President of scientific advisory board of MILDT. Member of scientific committee of the European Observatory of Drugs and Toxicomanies.
He is Laureate for the Prize of the European College of Neurospsychopharmacology (September 2009) for his work and new hypothesis of neurobiological mechanisms of addiction. -
Prof Alain PUECH
Read moreKT clinical project director
Ph. D. in Pharmacology and a Medical Doctor and has held a number of key positions in his over 30 year career in the pharmaceutical industry including :- Professor at the CHU Pitié-Salpétrière(1971-1997).
- Manager of the International development at Sanofi -Synthelabo (1997-2003).
- Chief Scientific Officer France Sanofi Aventis (2003-2006).
-
Prof Bernard PAU
Read moreKT Business development advisor
Professor in Immunology and Biotechnology at the University of Montpellier (Faculty of Pharmaceutical sciences); has pioneered in France the transfer of innovation by bridging the gap between academic research and industry in the fields of drug discovery, diagnostic tests and biotechnology; former director of the department of Life sciences at CNRS; formerly with Sanofi Pharmaceutical Group; co-founder of two startup companies: Innodia and I2T; co-author of more than 140 scientific publications and patents; inventor of innovative worldwide marketed diagnostic tests. -
Dr Sylvain YON
Read moreKT Business development advisor
Sylvain Yon, Ph.D. is the Deputy CEO of Theraclion (www.theraclion.com). In this role, he leads both the research & development efforts of the company and the business expansion on the Asian markets. Sylvain Yon is a co-founder of Echosens, where he headed engineering activities until 2008. He then successfully handled the company’s acquisition by a major player in the Chinese health industry, before joining Theraclion. He is also the founder of several companies in the fields of acoustics and the Internet -
Lucas Biela
Read moreKinnov Therapeutics Clinical Project Manager
14+ years of experience in clinical research. Previous experience at Parexel, Onxeo, Danone Research, DBV Technologies